Research and Trials
01 Jan 2013
PRIDE – Prograf Investigation of Diet and Exercise. A Pilot Trial of the Effect of Dietary and Exercise Intervention in Patients Who Have Received a Renal Transplant on Tacrolimus (Prograf)
The purpose of this trial is to investigate whether a combined dietary and exercise intervention, added to standard care, reduces the expected frequency of insulin resistance in kidney transplant recipients on tacrolimus. Official Title A Pilot Trial of the Effect of Dietary and Exercise Intervention on Insulin Resistance and Metabolic…
Research and Trials
01 Jan 2013
Audit of the Effect of Changing From Intravenous to Subcutaneous Administration of Erythropoeisis Stimulating Agents in Haemodialysis Patients
The purpose of this study is to audit the effects of changing all haemodialysis patients from intravenous to subcutaneous administration of ESA’s, to ensure that a cost-saving is achieved and that this does not occur at the expense of anaemia control. The dose changes will occur according to usual clinical…
Blood
01 Jan 2013
A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia
This study will determine whether 8 weekly monitoring of hemoglobin and iron parameters in the correction phase of NeoRecormon therapy in patients with renal anemia is as safe and effective as 4 weekly monitoring. Patients with chronic kidney disease will receive NeoRecormon at a dose aimed at achieving and maintaining…
Men's Health
01 Jan 2013
Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder.
This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder. Patients will complete a series of questionnaires before treatment, during treatment and after treatment, to assess whether UK-369,003 has improved their symptoms of overactive bladder and erectile…
Cancer
01 Jan 2013
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 in adult subjects with locally recurrent or metastatic clear-cell Renal Cell Carcinoma (RCC). Official Title A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or…
Research and Trials
01 Jan 2013
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals. Official Title A Randomized, Open-Label Study Comparing the Effects of Low-Dose…
Hormones
01 Jan 2013
E.V.O.L.V.E. Trial: EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events
This study will evaluate the effects of cinacalcet (cincalcet HCl or Sensipar/Mimpara) on cardiovascular events and death in chronic kidney disease (CKD) patients with secondary hyperparathryoidism (HPT) who are receiving dialysis. Official Title EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events Conditions Secondary Hyperparathyroidism, Chronic Kidney Disease Study Type…
Hormones
01 Jan 2013
The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes
This study will compare insulin lispro low mixture and insulin glargine in combination with the patient’s oral diabetes medicines for their ability to control blood sugar in patients with type 2 diabetes and compare insulin lispro LM to insulin glargine with regard to the length of time that the overall…
Blood
01 Jan 2013
Super High-Flux – High Volume Dialysis in Sepsis-Induced Acute Renal Failure
We wish to compare the effect of using new large hole filters with hemodialysis in patients with severe infections and acute kidney failure to that of standard filters. The new therapy will be considered to be effective if it lowers the amount of drugs used to support blood pressure and…
